Lauren Santye, Assistant Editor

Bacterium may hold the key to preventing resistance to chemotherapy.

Imbruvica is the first FDA-approved therapy to treat cGVHD.

Scientists say ring containing pre-exposure prophylaxis and Truvada is safe in US teens, now need data in African adolescent girls.

The label has been updated to include data from adults co-infected with hepatitis C virus and HIV-1.

Top news of the day from across the health care landscape.

Enasidenib, an oral inhibitor for relapsed or refractory acute myeloid leukemia, shows promise in achieving a complete response with hematologic improvement.

New treatment strategies for rheumatoid arthritis led to a reduction in congestive heart failure and cardiovascular mortality after the year 2000.

Combining old and new technology may provide superior oncologic outcomes for patients with resectable lung cancer.

Study will compare the pharmacokinetics and clinical outcomes between Humira biosimilar and its reference product in the treatment of moderate-to-severe chronic plaque psoriasis.

Top news of the day from across the health care landscape.

Increased efforts in prevention and treatment for HIV show promise in high-burden regions.

The upcoming National Association of Specialty Pharmacy conference will focus on the evolution of the industry.

Top news of the day from across the health care landscape.

More than half of survey respondents with HIV reported concerns about possible drug-drug interactions.

Technique offers improved survival in patients with advanced, inoperable stage 3 non-small cell lung cancer.

One-third of strokes worldwide occur in stroke survivors.

HIV patients lack crucial peroxisomal proteins in the brain.

Top news of the day from across the health care landscape.

Approximately 325 million individuals are living with hepatitis worldwide.

Those who battled hepatitis C recount their journey to spread awareness on World Hepatitis Day.

The annual meeting of the National Association of Specialty Pharmacy will take place this September in Washington, DC.

Response rate higher among patients with HIV treated with dolutegravir compared with lopinavir/ritonavir.

Top news of the day from across the health care landscape.

Dolutegravir-based treatment non-inferior to boosted protease inhibitor regimen in virally suppressed HIV-positive patients.

Investigators compare long-term overall and disease-free survival rates in neoadjuvant versus adjuvant radiotherapy.

Top news of the day from across the health care landscape.

Fixed-dose combination tablet containing doravirine achieved viral suppression in HIV-1 infected treatment-naïve adults.

Immunization of cows induces rapid elicitation of broadly neutralizing antibodies to HIV.

Novel approach may improve efficacy of pancreatic cancer treatments.

Tools that analyze the cancer genome provide new insight into the mechanisms that drive cancer development.